Kura Oncology, Inc.: insider trades · United States · SEC (Form 4)

About Kura Oncology, Inc.

Kura Oncology, Inc. (ticker: KURA) is a U.S.-based biopharmaceutical company listed on the Nasdaq market in the United States. Founded in 2014 and headquartered in San Diego, California, the company built its reputation as a clinical-stage oncology drug developer focused on precision medicine. Over time, it has evolved from a pure R&D story into a more mature biotech with an approved product and an emerging commercial footprint. Its overall strategy is centered on genetically defined cancer subtypes, biomarker-driven development, and targeted small-molecule therapies. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001422143/000119312526092567/kura-20251231.htm?utm_source=openai)) Kura’s core portfolio is designed to inhibit cancer signaling pathways and address major unmet needs in hematologic malignancies and solid tumors. The company’s lead asset is KOMZIFTI™ (ziftomenib), an oral menin inhibitor. In November 2025, the FDA approved ziftomenib for adults with relapsed or refractory acute myeloid leukemia (AML) harboring an NPM1 mutation, and Kura has stated that the product is being marketed in the United States under the KOMZIFTI brand. The program was developed with Kyowa Kirin, which also supports commercialization and adds external validation to the asset. Beyond ziftomenib, Kura continues to advance its farnesyl transferase inhibition platform, including tipifarnib and darlifarnib (KO-2806), with a focus on rational combinations and resistance mechanisms in oncology. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ziftomenib-relapsed-or-refractory-acute-myeloid-leukemia-npm1-mutation?utm_source=openai)) From a competitive standpoint, Kura Oncology occupies a specialized niche within precision oncology. Its key strengths are a focused scientific model, a validated commercial asset, and a pipeline built around clear genetic drivers of disease. That said, the company still operates in a highly competitive and capital-intensive sector. Its future depends heavily on the uptake of KOMZIFTI, the breadth of its label and market penetration, and the ability of its remaining pipeline to generate additional late-stage value. Like many oncology biotechs, Kura faces risks related to clinical execution, regulatory follow-through, commercial adoption, reimbursement dynamics, and competition from larger or better-capitalized peers. ([ir.kuraoncology.com](https://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-reports-fourth-quarter-and-full-year-2025?utm_source=openai)) Recent milestones are important for investors: FDA acceptance of the NDA in mid-2025, FDA approval in November 2025, the first U.S. commercial sale shortly thereafter, and subsequent corporate updates highlighting launch execution and preliminary revenue metrics. These events mark a meaningful transition for Kura from development-stage biotech to a company with an approved oncology product and a growing U.S. commercial presence. For French-speaking investors, the key takeaway is that Kura Oncology is now a Nasdaq-listed U.S. cancer biotech with a differentiated product story, but its valuation remains highly sensitive to launch execution and pipeline progress. ([ir.kuraoncology.com](https://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-and-kyowa-kirin-announce-fda-acceptance-and?utm_source=openai))